CYP2D6 Genotyping and the Use of Tamoxifen in Breast Cancer

被引：12

作者：

Berry, Donald ^{[1
]}

机构：

[1] Univ Texas MD Anderson Canc Ctr, Dept Biostat, Houston, TX 77030 USA

来源：

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE | 2013年 / 105卷 / 17期

关键词：

GROUP; 1-98; TRIAL; POSTMENOPAUSAL WOMEN; RE CYP2D6; UGT2B7; GENOTYPE; RECURRENCE; RISK;

D O I：

10.1093/jnci/djt221

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：1267 / 1269

页数：4

共 15 条

[1] Tamoxifen Use in Postmenopausal Breast Cancer: CYP2D6 Matters [J].

Brauch, Hiltrud ;

Schroth, Werner ;

Goetz, Matthew P. ;

Muerdter, Thomas E. ;

Winter, Stefan ;

Ingle, James N. ;

Schwab, Matthias ;

Eichelbaum, Michel .

JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (02) :176-180

[2] Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials [J].

Davies, C. ;

Godwin, J. ;

Gray, R. ;

Clarke, M. ;

Darby, S. ;

McGale, P. ;

Wang, Y. C. ;

Peto, R. ;

Pan, H. C. ;

Cutter, D. ;

Taylor, C. ;

Ingle, J. .

LANCET, 2011, 378 (9793) :771-784

[3] Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes [J].

Goetz, MP ;

Rae, JM ;

Suman, VJ ;

Safgren, SL ;

Ames, MM ;

Visscher, DW ;

Reynolds, C ;

Couch, FJ ;

Lingle, WL ;

Flockhart, DA ;

Desta, Z ;

Perez, EA ;

Ingle, JN .

JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (36) :9312-9318

[4] CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment [J].

Jin, Y ;

Desta, Z ;

Stearns, V ;

Ward, B ;

Ho, H ;

Lee, KH ;

Skaar, T ;

Storniolo, AM ;

Li, L ;

Araba, A ;

Blanchard, R ;

Nguyen, A ;

Ullmer, L ;

Hayden, J ;

Lemler, S ;

Weinshilboum, RM ;

Rae, JM ;

Hayes, DF ;

Flockhart, DA .

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2005, 97 (01) :30-39

[5]

Kelly CM, 2012, J NATL CANCER I, V104, P1268, DOI 10.1093/jnci/djs303

[6] CYP2D6 Genotype as a Marker for Benefit of Adjuvant Tamoxifen in Postmenopausal Women: Lessons Learned [J].

Kelly, Catherine M. ;

Pritchard, Kathleen I. .

JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2012, 104 (06) :427-428

[7] Re: CYP2D6 Genotype and Tamoxifen Response in Postmenopausal Women With Endocrine-Responsive Breast Cancer: The Breast International Group 1-98 Trial [J].

Nakamura, Yusuke ;

Ratain, Mark J. ;

Cox, Nancy J. ;

Mcleod, Howard L. ;

Kroetz, Deanna L. ;

Flockhart, David A. .

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2012, 104 (16) :1264-1264

[8] Re: CYP2D6 Genotype and Tamoxifen Response in Postmenopausal Women With Endocrine-Responsive Breast Cancer: The Breast International Group 1-98 Trial and Re: CYP2D6 and UGT2B7 Genotype and Risk of Recurrence in Tamoxifen-Treated Breast Cancer Patients [J].

Pharoah, Paul D. P. ;

Abraham, Jean ;

Caldas, Carlos .

JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2012, 104 (16) :1263-1264

[9] Concordance Between CYP2D6 Genotypes Obtained From Tumor-Derived and Germline DNA [J].

Rae, James M. ;

Regan, Meredith M. ;

Thibert, Jacklyn N. ;

Gersch, Christina ;

Thomas, Dafydd ;

Leyland-Jones, Brian ;

Viale, Giuseppe ;

Pusztai, Lajos ;

Hayes, Daniel F. ;

Skaar, Todd ;

Van Poznak, Catherine .

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2013, 105 (17) :1332-1334

[10]

Rae JM, 2012, J NATL CANCER I, V104, P1267, DOI 10.1093/jnci/djs302

← 1 2 →